Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Umbilical cord mesenchymal stem cell therapy - Kangstem Biotech

X
Drug Profile

Umbilical cord mesenchymal stem cell therapy - Kangstem Biotech

Alternative Names: FURESTEM; FURESTEM-AD; FURESTEM-AD inj; FURESTEM-CD; FURESTEM-CD Inj; FURESTEM-OA Kit Inj; FURESTEM-RA; hUCB-MSCs

Latest Information Update: 04 Sep 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kangstem Holdings
  • Developer Daewoong Pharmaceutical; Kangstem Biotech
  • Class Mesenchymal stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Atopic dermatitis
  • Phase II Rheumatoid arthritis
  • Phase I/II Crohn's disease; Epidermolysis bullosa dystrophica
  • No development reported Plaque psoriasis
  • Discontinued Amyotrophic lateral sclerosis; Cancer; Diabetes mellitus; Niemann-Pick diseases; Pain; Retinal disorders

Most Recent Events

  • 31 Aug 2023 Kang Stem Biostem plans a follow-up observational trial (K0701-E) for Knee Osteoarthritis who participated in K0701 trial (NCT06013306)
  • 14 Jul 2023 Kangstem Biotech plans a phase I/II trial for Osteoarthritis (Intra-articular) (NCT05944627)
  • 06 Jul 2023 Kang Stem Biotech plans a phase I/II trial K0701 for Knee Osteoarthritis (NCT05944627)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top